Operating Income (Loss) in USD of aTYR PHARMA INC from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
aTYR PHARMA INC quarterly/annual Operating Income (Loss) history and change rate from 2013 to Q3 2025.
  • aTYR PHARMA INC Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$26.7M, a 47.4% decline year-over-year.
  • aTYR PHARMA INC Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$78.7M, a 15.6% decline year-over-year.
  • aTYR PHARMA INC annual Operating Income (Loss) for 2024 was -$67.9M, a 23.7% decline from 2023.
  • aTYR PHARMA INC annual Operating Income (Loss) for 2023 was -$54.9M, a 18.4% decline from 2022.
  • aTYR PHARMA INC annual Operating Income (Loss) for 2022 was -$46.4M, a 36.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

aTYR PHARMA INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$78.7M -$26.7M -$8.6M -47.4% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$70M -$20.3M -$3M -17.3% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$67.1M -$15.8M +$863K +5.19% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$67.9M -$15.8M +$139K +0.87% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025
Q3 2024 -$68.1M -$18.1M -$5.53M -43.8% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$62.5M -$17.3M -$3.76M -27.7% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$58.8M -$16.6M -$3.85M -30.1% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$54.9M -$16M -$8.01M -101% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025
Q3 2023 -$46.9M -$12.6M +$877K +6.5% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$47.8M -$13.6M -$974K -7.74% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$46.8M -$12.8M -$409K -3.3% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q4 2022 -$46.4M -$7.95M +$690K +7.99% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025
Q3 2022 -$47.1M -$13.5M -$5.76M -74.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$41.3M -$12.6M -$2.14M -20.5% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$39.2M -$12.4M -$5.18M -71.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023
Q4 2021 -$34M -$8.64M -$3.7M -74.9% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024
Q3 2021 -$30.3M -$7.73M -$1.22M -18.7% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$29.1M -$10.4M -$4.13M -65.3% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$25M -$7.2M -$9.06M -487% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 -$15.9M -$4.94M +$1.02M +17.1% 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2023
Q3 2020 -$16.9M -$6.51M -$1.01M -18.4% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$15.9M -$6.32M -$677K -12% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021
Q1 2020 -$15.2M $1.86M +$7.74M 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021
Q4 2019 -$23M -$5.96M +$1K +0.02% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2022
Q3 2019 -$23M -$5.5M +$1.18M +17.7% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 -$24.2M -$5.64M +$4.32M +43.4% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020
Q1 2019 -$28.5M -$5.88M +$4.34M +42.5% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020
Q4 2018 -$32.8M -$5.96M +$5.24M +46.8% 01 Oct 2018 31 Dec 2018 10-K 24 Mar 2021
Q3 2018 -$38.1M -$6.68M +$4.15M +38.3% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 -$42.2M -$9.96M +$1.95M +16.4% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019
Q1 2018 -$44.2M -$10.2M +$2.99M +22.6% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019
Q4 2017 -$47.1M -$11.2M +$1.33M +10.6% 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2020
Q3 2017 -$48.5M -$10.8M +$3.04M +21.9% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$51.5M -$11.9M +$3.53M +22.8% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$55M -$13.2M +$2.9M +18% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q4 2016 -$57.9M -$12.5M +$3.96M +24% 01 Oct 2016 31 Dec 2016 10-K 26 Mar 2019
Q3 2016 -$61.9M -$13.9M -$2.55M -22.6% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 -$59.3M -$15.4M -$4.54M -41.6% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 -$54.8M -$16.1M -$7.19M -80.6% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017
Q4 2015 -$47.6M -$16.5M -$10.5M -173% 01 Oct 2015 31 Dec 2015 10-K 20 Mar 2018
Q3 2015 -$37.2M -$11.3M -$5.08M -81.6% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$32.1M -$10.9M -$5.54M -103% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016
Q1 2015 -$26.5M -$8.92M -$2.99M -50.5% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016
Q4 2014 -$23.6M -$6.03M 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017
Q3 2014 -$6.23M 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015
Q2 2014 -$5.36M 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2015
Q1 2014 -$5.93M 01 Jan 2014 31 Mar 2014 10-Q 18 Jun 2015

aTYR PHARMA INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$67.9M -$13M -23.7% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025
2023 -$54.9M -$8.52M -18.4% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025
2022 -$46.4M -$12.4M -36.4% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025
2021 -$34M -$18.1M -114% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024
2020 -$15.9M +$7.07M +30.8% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2023
2019 -$23M +$9.84M +30% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2022
2018 -$32.8M +$14.3M +30.4% 01 Jan 2018 31 Dec 2018 10-K 24 Mar 2021
2017 -$47.1M +$10.8M +18.6% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2020
2016 -$57.9M -$10.3M -21.7% 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2019
2015 -$47.6M -$24.1M -102% 01 Jan 2015 31 Dec 2015 10-K 20 Mar 2018
2014 -$23.6M -$4.01M -20.5% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017
2013 -$19.5M 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.